This is the vaccine that Kenya has been taking part in its development through the Kenya Medical Research Institute Wellcome Trust-Kilifi. AstraZeneca said the authorisation was for a two dose regime and that the vaccine had been approved for use for emergency supply. Researchers said that the finding of 90 per cent efficacy for the low-dose/high-dose regime needed more investigation. AstraZeneca did not specify which dose regime had been approved. Last week, the Kenyan government said it will spend Sh10 billion to purchase 12 million doses of the vaccine.

Source: Standard Digital December 30, 2020 10:41 UTC